

FDA-APPROVED COLORECTAL CANCER TREATMENTS

Generic & Class	Brand & Company	Strength	Form	Usual Dose*
Alkylating agents				
Oxaliplatin	Eloxatin (Sanofi Aventis)	5mg/mL	soln for IV infusion after dilution	Day 1: 85mg/m ² + leucovorin, followed by 5-FU. Day 2: Leucovorin followed by 5-FU. Give by IV infusion every two weeks for a total of 6 months (eg, 12 cycles).
Antimetabolites				
Capecitabine	Xeloda (Genentech)	150mg, 500mg	tabs	1250mg/m ² twice daily for 2 weeks on and 1 week off, for a total of 8 cycles
Fluorouracil	(various)	50mg/mL	soln for IV inj	12mg/kg once daily for 4 successive days; max 800mg/day. If no toxicity, then 6mg/kg on days 6, 8, 10, 12; stop after day 12. Discontinue if toxicity occurs.
Folic acid derivative				
Leucovorin	Leucovorin (Teva)	100mg, 350mg	lyophilized pwd for IV or IM inj reconstitution	200mg/m ² by slow IV inj over a minimum of 3min followed by 5-fluorouracil (370mg/m ²); or 20mg/m ² IV followed by 5-fluorouracil (425mg/m ²); both regimens: daily for 5 days, may be repeated at 4 week intervals for 2 courses and then repeated at 4-5 week intervals
Levoleucovorin	Fusilev (Spectrum)	50mg/vial 175mg/17.5mL, 250mg/25mL	lyophilized powder for IV inj after reconstitution soln for IV inj	100mg/m ² by slow IV inj over a minimum of 3min, followed by 5-FU at 370mg/m ² by IV inj; or 10mg/m ² by IV inj followed by 5-FU at 425mg/m ² by IV inj. Administer 5-FU separately to avoid precipitate formation. Treat daily for 5 weeks; may repeat at 4-week intervals for 2 courses, then at 4-5 intervals.
Fusion Protein				
Ziv-aflibercept	Zaltrap (Sanofi and Regeneron)	25mg/mL	soln for IV infusion after dilution	4mg/kg as an IV infusion over 1 hour every 2 weeks; continue until disease progression or unacceptable toxicity.
Monoclonal antibodies				
Bevacizumab	Avastin (Genentech)	100mg, 400mg	soln for IV infusion after dilution	5mg/kg (with bolus-IFL) or 10mg/kg (with FOLFOX-4) once every 14 days until disease progression detected; 1st infusion over 90min, 2nd infusion over 60min, subsequent infusion over 30min.
Cetuximab	Erbix (Bristol Myers Squibb)	100mg, 200mg	soln for IV infusion	Loading dose: 400mg/m ² once over 2 hours; then 250mg/m ² once weekly over 1 hour
Panitumumab	Vectibix (Amgen)	20mg/mL	soln for IV infusion after dilution	6mg/kg as IV inf over 60min once every 14 days until disease progression detected. Dose >100mg over 90min.*
Topoisomerase inhibitors				
Irinotecan	Camptosar (Pfizer)	20mg/mL	soln for IV infusion after dilution	Combination therapy (with 5-FU and leucovorin): 125mg/m ² on days 1, 8, 15, 22; or, 180mg/m ² on days 1, 15, 29; both: give every 6 weeks. Monotherapy: 125mg/m ² on days 1, 8, 15, 22, then 2-week rest; or, 350mg/m ² once every 3 weeks.

NOTES

*For more detailed dosing information, see drug entry.

(Rev. 9/2012)